Clinical Trials Browser

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT01220154 2025-02-21

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Phase 1 Completed

9 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00708448 2025-02-13

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Phase 1 Completed

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06232902 2024-12-18

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Phase 1 Completed

84 enrolled

Tumor-Agnostic

Neoplasms

NCT02848443 2024-07-25

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Phase 1 Completed

78 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT03250832 2024-04-11

CITRINO

Phase 1 Completed

111 enrolled 48 charts

GastrointestinalGynecologicThoracic

Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

50 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Phase 1 Completed

7 enrolled

Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT02313272 2023-10-23

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Phase 1 Completed

32 enrolled 12 charts

CNS

Glioma, Neoplasms, Neurologic Manifestations

NCT05431582 2023-06-15

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1 Withdrawn

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03082209 2022-12-09

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Phase 1 Completed

153 enrolled

GastrointestinalLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT02010606 2021-11-22

Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

Phase 1 Completed

39 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Neoplasms

NCT01633970 2020-10-08

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

240 enrolled

Tumor-Agnostic

Neoplasms

NCT01514123 2020-09-17

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Phase 1 Completed

43 enrolled

Tumor-Agnostic

Neoplasms

NCT00095459 2019-12-17

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

Phase 1 Completed

57 enrolled

Tumor-Agnostic

Neoplasms

NCT01251926 2019-11-15

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

Phase 1 Completed

12 enrolled

Tumor-Agnostic

Neoplasms

NCT03659305 2019-02-05

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Phase 1 Completed

80 enrolled

Tumor-Agnostic

Neoplasms

NCT01274624 2018-12-19

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Phase 1 Completed

36 enrolled

Tumor-Agnostic

Neoplasms

NCT01705002 2018-07-10

Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.

Phase 1 Completed

88 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01219777 2018-02-08

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Phase 1 Completed

9 enrolled 7 charts

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00992121 2017-11-13

An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma

Phase 1 Completed

11 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT02250118 2017-11-06

BEVAP

Phase 1 Terminated

1 enrolled

BreastThoracic

Breast Neoplasms, Neoplasms, Pleural Effusion, Malignant

NCT02640365 2017-01-31

DOUBLIRI

Phase 1 Completed

10 enrolled

Tumor-Agnostic

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

104 enrolled

Tumor-Agnostic

Neoplasms

NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

172 enrolled 13 charts

Lymphoid

Lymphoma, Neoplasms

NCT00809133 2016-03-14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Phase 1 Completed

83 enrolled 42 charts

Tumor-Agnostic

Neoplasms

NCT01057264 2015-11-18

HAI Abraxane With Gemcitabine and Bevacizumab

Phase 1 Completed

78 enrolled

Tumor-Agnostic

Neoplasms

NCT00968240 2015-04-22

Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

Phase 1 Completed

30 enrolled

CNS

Astrocytoma, Glioblastoma, Neoplasms

NCT01193595 2014-12-03

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Phase 1 Completed

39 enrolled

Tumor-Agnostic

Neoplasms

NCT02031991 2014-08-15

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

Phase 1 Completed

102 enrolled

Tumor-Agnostic

Neoplasms

NCT01069328 2013-11-13

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

33 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00666692 2012-04-27

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

7 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00395434 2011-10-31

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Phase 1 Completed

20 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01271166 2011-01-06

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Phase 1 Terminated

10 enrolled

Tumor-Agnostic

Neoplasms

NCT00611793 2009-01-23

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Phase 1 Completed

50 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

EGRET

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

PanTumor-101

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

CITRINO

PTST_PALBEVA

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma

BEVAP

DOUBLIRI

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

HAI Abraxane With Gemcitabine and Bevacizumab

Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies